Treatment

JAB-21822 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation
This study is testing a new drug, JAB-21822, for adults with advanced solid cancers that have a specific genetic change (KRAS G12C mutation). Researchers want to see how safe the drug is, what side effects it might cause, and if it could help shrink tumours.
For: advanced solid tumors with KRAS G12C mutation
Spain